Major Depressive Disorder – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Major Depressive Disorder – Pipeline Review, H2 2016’, provides an overview of the Major Depressive Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder

The report reviews pipeline therapeutics for Major Depressive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Major Depressive Disorder therapeutics and enlists all their major and minor projects

The report assesses Major Depressive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Major Depressive Disorder

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aequus Pharmaceuticals Inc.

Alkermes Plc

Allergan Plc

Angelini Group

Avanir Pharmaceuticals, Inc.

Azevan Pharmaceuticals, Inc.

BioCrea GmbH

BioLite, Inc.

Bristol-Myers Squibb Company

Cerecor Inc.

Clera Inc.

Fabre-Kramer Pharmaceuticals, Inc.

GlaxoSmithKline Plc

H. Lundbeck A/S

Hua Medicine (Shanghai) Ltd.

Intra-Cellular Therapies, Inc.

Johnson & Johnson

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Luye Pharma Group Ltd.

Mapreg S.A.S.

Methylation Sciences Inc.

miCure Therapeutics Ltd.

Mitsubishi Tanabe Pharma Corporation

Neuralstem, Inc.

nLife Therapeutics, S.L.

Otsuka Holdings Co., Ltd.

Pherin Pharmaceuticals, Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

Saniona AB

Suven Life Sciences Ltd.

Takeda Pharmaceutical Company Limited

TRImaran Pharma, Inc.

Turing Pharmaceuticals AG

VistaGen Therapeutics , Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Major Depressive Disorder Overview 6

Therapeutics Development 7

Major Depressive Disorder - Therapeutics under Development by Companies 9

Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes 11

Major Depressive Disorder - Pipeline Products Glance 12

Major Depressive Disorder - Products under Development by Companies 15

Major Depressive Disorder - Products under Investigation by Universities/Institutes 18

Major Depressive Disorder - Companies Involved in Therapeutics Development 19

Major Depressive Disorder - Therapeutics Assessment 55

Drug Profiles 68

Major Depressive Disorder - Dormant Projects 174

Major Depressive Disorder - Discontinued Products 181

Major Depressive Disorder - Product Development Milestones 184

Appendix 194

List of Tables

List of Tables

Number of Products under Development for Major Depressive Disorder, H2 2016 13

Number of Products under Development for Major Depressive Disorder – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H2 2016 24

Major Depressive Disorder – Pipeline by Aequus Pharmaceuticals Inc., H2 2016 25

Major Depressive Disorder – Pipeline by Alkermes Plc, H2 2016 26

Major Depressive Disorder – Pipeline by Allergan Plc, H2 2016 27

Major Depressive Disorder – Pipeline by Angelini Group, H2 2016 28

Major Depressive Disorder – Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 29

Major Depressive Disorder – Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 30

Major Depressive Disorder – Pipeline by BioCrea GmbH, H2 2016 31

Major Depressive Disorder – Pipeline by BioLite, Inc., H2 2016 32

Major Depressive Disorder – Pipeline by Bristol-Myers Squibb Company, H2 2016 33

Major Depressive Disorder – Pipeline by Cerecor Inc., H2 2016 34

Major Depressive Disorder – Pipeline by Clera Inc., H2 2016 35

Major Depressive Disorder – Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 36

Major Depressive Disorder – Pipeline by GlaxoSmithKline Plc, H2 2016 37

Major Depressive Disorder – Pipeline by H. Lundbeck A/S, H2 2016 38

Major Depressive Disorder – Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 39

Major Depressive Disorder – Pipeline by Intra-Cellular Therapies, Inc., H2 2016 40

Major Depressive Disorder – Pipeline by Johnson & Johnson, H2 2016 41

Major Depressive Disorder – Pipeline by Lead Discovery Center GmbH, H2 2016 42

Major Depressive Disorder – Pipeline by Les Laboratoires Servier SAS, H2 2016 43

Major Depressive Disorder – Pipeline by Luye Pharma Group Ltd., H2 2016 44

Major Depressive Disorder – Pipeline by Mapreg S.A.S., H2 2016 45

Major Depressive Disorder – Pipeline by Methylation Sciences Inc., H2 2016 46

Major Depressive Disorder – Pipeline by miCure Therapeutics Ltd., H2 2016 47

Major Depressive Disorder – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 48

Major Depressive Disorder – Pipeline by Neuralstem, Inc., H2 2016 49

Major Depressive Disorder – Pipeline by nLife Therapeutics, S.L., H2 2016 50

Major Depressive Disorder – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 51

Major Depressive Disorder – Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 52

Major Depressive Disorder – Pipeline by Reviva Pharmaceuticals Inc., H2 2016 53

Major Depressive Disorder – Pipeline by Richter Gedeon Nyrt., H2 2016 54

Major Depressive Disorder – Pipeline by Saniona AB, H2 2016 55

Major Depressive Disorder – Pipeline by Suven Life Sciences Ltd., H2 2016 56

Major Depressive Disorder – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 57

Major Depressive Disorder – Pipeline by TRImaran Pharma, Inc., H2 2016 58

Major Depressive Disorder – Pipeline by Turing Pharmaceuticals AG , H2 2016 59

Major Depressive Disorder – Pipeline by VistaGen Therapeutics , Inc., H2 2016 60

Assessment by Monotherapy Products, H2 2016 61

Assessment by Combination Products, H2 2016 62

Number of Products by Stage and Target, H2 2016 64

Number of Products by Stage and Mechanism of Action, H2 2016 67

Number of Products by Stage and Route of Administration, H2 2016 71

Number of Products by Stage and Molecule Type, H2 2016 73

Major Depressive Disorder – Dormant Projects, H2 2016 180

Major Depressive Disorder – Dormant Projects (Contd..1), H2 2016 181

Major Depressive Disorder – Dormant Projects (Contd..2), H2 2016 182

Major Depressive Disorder – Dormant Projects (Contd..3), H2 2016 183

Major Depressive Disorder – Dormant Projects (Contd..4), H2 2016 184

Major Depressive Disorder – Dormant Projects (Contd..5), H2 2016 185

Major Depressive Disorder – Dormant Projects (Contd..6), H2 2016 186

Major Depressive Disorder – Discontinued Products, H2 2016 187

Major Depressive Disorder – Discontinued Products (Contd..1), H2 2016 188

Major Depressive Disorder – Discontinued Products (Contd..2), H2 2016 189

List of Figures

List of Figures

Number of Products under Development for Major Depressive Disorder, H2 2016 13

Number of Products under Development for Major Depressive Disorder – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy Products, H2 2016 61

Number of Products by Top 10 Targets, H2 2016 63

Number of Products by Stage and Top 10 Targets, H2 2016 63

Number of Products by Top 10 Mechanism of Actions, H2 2016 66

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 66

Number of Products by Routes of Administration, H2 2016 70

Number of Products by Stage and Routes of Administration, H2 2016 70

Number of Products by Molecule Types, H2 2016 72

Number of Products by Stage and Molecule Types, H2 2016 72

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared